You are here: Industry Insights > ImmunoPrecise

News List

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform prnasia
June 23, 2021
Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (EUFI.PA) company, and ImmunoPrecise Antibodies, the market leader in full-service therapeutic discovery and development ...
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease americanpharmaceuticalreview
April 09, 2021
IMMUNOPRECISE ANTIBODIES LTD. a leader in full-service, therapeutic antibody discovery and development, announced that its subsidiary Talem Therapeutics LLC has advanced development of a candidate panel of vetted, novel, therapeutic antibodies ...
ImmunoPrecise, Integrated Biotherapeutics, NIH Collaborate to Study Structural Details of Antibodies for COVID-19 americanpharmaceuticalreview
June 09, 2020
Immunoprecise Antibodies announced it is collaborating in a multi-company effort with the laboratory of Dr. Frederick Dyda at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) ...
ImmunoPrecise uses PolyTope mAb Therapy for Covid-19 pharmaceutical-technology
March 16, 2020
ImmunoPrecise Antibodies is set to use PolyTope mAb Therapy approach for the development of a universal COVID-19 therapy.
ImmunoPrecise acquires ModiQuest for €7M biospectrumasia
April 10, 2018
As a result of the acquisition of ModiQuest, ImmunoPrecise is now an innovative, integrated antibody solutions company focused on the next generation of technology behind therapeutic antibody discovery.
ImmunoPrecise Acquires ModiQuest Research BV biospace
April 08, 2018
ImmunoPrecise Antibodies LTD. is pleased to announce that it has acquired all of the issued and outstanding shares of ModiQuest Research BV ("ModiQuest")